Study population
We enrolled a cohort of forty-eight patients presenting with isolated
neurocardiogenic syncope characterized by a pronounced cardioinhibitory
component. Among them, 27 (56.3%) were female, and they had a
documented history of recurrent syncope episodes (5.1±2.5 per year)
causing significant impairment in their quality of life, despite prior
attempts at clinical and pharmacological interventions. All patients
received comprehensive information regarding available therapeutic
options and elected to undergo CNA rather than pacemaker implantation.
Inclusion Criteria:
Patients were required to meet the following criteria:
- Diagnosis of neurocardiogenic syncope with a substantial
cardioinhibitory component resulting in symptoms impacting quality of
life;
- Age ranging from 15 to 70 years;
- Refractoriness, impracticality, or ineffectiveness of pharmacological
treatment or pacemaker implantation;
- Willingness to provide written informed consent, participate in the
study, and comply with the follow-up protocol.
Exclusion Criteria:
Those who meet any of the following criteria were not included:
1. Previous cardiac surgery.
2. Presence of cardiomyopathy (EF < 55%; LA >
42mm).
3. Left ventricular hypertrophy (wall thickness >1.2 cm),
valvular, or coronary artery disease.
4. Contraindication for the use of anticoagulants (heparin or NOAC).
5. NYHA Heart Failure Class > I.
6. Cerebrovascular or important organic or metabolic disease.
8. Current or possible pregnancy in the next 3 months.